Section Arrow
Quote
COLL.NASDAQ
- Collegium Pharmaceutical
Quotes are at least 15-min delayed:2026/05/13 07:33 EDT
Pre Market
Last
 36.1
+0.41 (+1.15%)
Bid
32.49
Ask
39.95
High 36.99 
Low 34.01 
Volume 4 
Regular Hours (Closed)
Last
 35.69
-0.12 (-0.34%)
Day High 
36.42 
Prev. Close
35.81 
1-M High
40.5 
Volume 
492.62K 
Bid
32.49
Ask
39.95
Day Low
34.72 
Open
35.75 
1-M Low
31.8713 
Market Cap 
1.16B 
Currency 美元 
P/E 17.33 
%Yield -- 
10-SMA 35.4 
20-SMA 34.51 
50-SMA 34.91 
52-W High 50.7866 
52-W Low 28.339 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.06/6.41
Enterprise Value
1.95B
Balance Sheet
Book Value Per Share
9.63
Cash Flow
Cash Flow Yield
0.22
Income Statement
Total Revenue
780.57M
Operating Revenue Per Share
16.85
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health25.03-4.11-14.10%57.14PE
Pre Market 24.85 -0.18 -0.72%
ZTSZOETIS76.94+0.27+0.35%12.61PE
Pre Market 77.1 +0.16 +0.21%
CPHIChina Pharma Holdings Inc0.8927+0.35855+67.13%-- 
Pre Market 0.8443 -0.0484 -5.42%
VTRSViatris17.17+0.25+1.48%-- 
Pre Market 17.13 -0.04 -0.23%
ELANElanco Animal Health21.43-0.29-1.34%-- 
Pre Market 22.9 +1.47 +6.86%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.